Neurocrine Biosciences, Inc. Delays Indiplon Application To Summer 2008

November 3, 2006 |

1 min read

Nov 2 (Reuters) - Neurocrine Biosciences Inc. (NBIX.O: Quote, Profile, Research) on Thursday delayed the re-submission for approval of its experimental sleep drug indiplon to summer 2008.

>>> Discuss This Story

Regulatory

MORE ON THIS TOPIC

Illustration of man walking in the beach between two blue seas, surreal abstract path concept

Rare disease

FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases

February 23, 2026

·

3 min read

·

Nick Paul Taylor

Contemporary art collage. Businessmen, employees walking into open door symbolizing new opportunities. Way to success. Concept of business, promotion, motivation, ambitions and ideas

Government

Kennedy Ally Departs CDC Amid Leadership Shake-Up

February 23, 2026

·

1 min read

·

Annalee Armstrong

Conceptual origami paper plane pulling business finance growth chart line flying upwards on blue sky background.

Approvals

Vanda Rebounds From Jet Lag Rejection With FDA Nod for Bipolar, Schizophrenia Drug

February 23, 2026

·

2 min read

·

Tristan Manalac

Collage halftone banner with two hands that put objects on scales. Halftone hands holding circle and square and put them on the scales. Concept of business balance in teamwork. Vector illustration.

Legal

REGENXBIO Secures Legal Win in Gene Therapy Patent Battle Vs. Sarepta

February 23, 2026

·

2 min read

·

Tristan Manalac